New notification of ‘tight supply’ of EpiPens, as stock shortages continue
The TGA has renewed its advice about continuing issues with the supply of EpiPens in Australia.
In the latest notification, issued on Monday, the TGA says: “Alphapharm Pty Ltd (trading as Mylan Australia), has confirmed that, while supply to wholesalers is increasing, there continues to be tight supply of EpiPens”.
“Patients who are still having difficulty obtaining an EpiPen should contact their pharmacy for assistance,” the TGA advice continues.
“Mylan has advised that, as a back-up, pharmacies can still follow instructions provided online by Mylan Australia to assist patients”.
The latest notification said the situation remained similar, and advice current from its previous notification of “constrained EpiPen supply” on 28 April.
In this notification, it was advised that supply of EpiPen 300 mcg is “constrained due to manufacturing delays. Stock levels will not return to normal for some months”.
Supply of EpiPen Jnr 150 mcg was not affected.
Mylan has added that its dedicated EpiPen Customer Service Toll-Free hotline on 1800 931 625 is still available for pharmacies.
The company is advising pharmacies to refresh EpiPen 300 mcg Adrenaline (epinephrine) Auto-Injector orders with wholesalers on a weekly basis, as “backorders are being cancelled after any partial shipment of stock”.
Click here for more information
